NNVC Key Stats
Street Insider08/21 09:29
Street Insider08/19 08:00
Street Insider08/15 12:25
Street Insider08/15 10:51
Street Insider08/15 08:58
Street Insider08/14 15:16
Street Insider08/14 10:12
Street Insider08/13 16:28
Street Insider08/13 12:28
|12/09/2013||Misc||AGM Event for NanoViricides Inc|
NNVC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Nanoviricides is up 6.28% over the last year vs S&P 500 Total Return up 23.11%, Biocryst Pharmaceuticals up 125.1%, and Sarepta Therapeutics down 33.50%.
Balance Sheet View Statement
Y-Ratings for NNVC
Portfolio Strategies Featuring NNVC
Did Nanoviricides make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Company Website: http://www.nanoviricides.com
- IR Website: http://www.nanoviricides.com/investorinfo.html
- HQ Country: United States
- HQ State/Province: Connecticut
- Incorporation Country: United States
- Incorporation State/Province: Nevada
- Est. Current Fiscal Quarter End: September 30, 2014
- Est. Current Fiscal Year End: June 30, 2015
- Last Fiscal Quarter End: June 30, 2013
- Last Fiscal Year End: June 30, 2013
- NAICS: Pharmaceutical Preparation Manufacturing
- NAICS Code: 325412
- NAICS Industry: Pharmaceutical and Medicine Manufacturing
- NAICS Sector: Manufacturing
NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States.
NNVC Excel Add-In Codes
- Name: =YCI("NNVC","name")
- Description: =YCI("NNVC","description")
- Sector: =YCI("NNVC","sector")
- Industry: =YCI("NNVC","industry")
- Est. Current Fiscal Year End: =YCI("NNVC","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.